Canada markets closed

Avivagen Inc. (VIV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.00500.0000 (0.00%)
At close: 10:30AM EDT
Full screen
Previous Close0.0050
Open0.0050
Bid0.0050 x 0
Ask0.0050 x 0
Day's Range0.0050 - 0.0050
52 Week Range0.0050 - 0.0300
Volume2,820
Avg. Volume8,309
Market Cap388,474
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings DateApr 29, 2024 - May 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Avivagen Makes Voluntary Assignment into Bankruptcy Under the BIA

    Ottawa, Ontario--(Newsfile Corp. - April 24, 2024) - Avivagen Inc. (TSXV: VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance feed intake and support immune function, thereby supporting general health and performance, announced today that is has made a voluntary assignment in bankruptcy for the benefit of its creditors pursuant to section 49 of the Bankruptcy

  • Business Wire

    Avivagen Announces New 500Kg Order for OxC-beta™

    OTTAWA, Ontario, October 17, 2023--Avivagen Inc. (TSXV.VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce a 500kg order for OxC-beta™. The purchase follows a 500kg order in July from the same customer, based in Taiwan, for use within the sow ma

  • Business Wire

    Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2023

    OTTAWA, Ontario, September 29, 2023--Avivagen Inc. (TSXV:VIV) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2023.